Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1408

Sort by

Sort Order Select

Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Blood (2019) 134 (23): 2036–2045.

https://doi.org/10.1182/blood.2019000069

Published: 2019

Includes: Supplemental data

Journal Articles

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Blood (2019) 134 (Supplement_1): 661.

https://doi.org/10.1182/blood-2019-126767

Published: 2019

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Jerald P. Radich, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Michael W. Deininger, Javier Pinilla Ibarz, MD PhD, Daniel J. DeAngelo, MD PhD, Susan Branford, PhD FFSc (RCPA), Islam Sadek, Shalini Chaturvedi, Manu Sondhi, MD PhD, Matthew Wall, Kaushal Mishra, PhD, Das Purkayastha, PhD, Alok Shrestha, Vanessa Obourn, Brian S. White, Brian J. Druker

Blood (2019) 134 (Supplement_1): 665.

https://doi.org/10.1182/blood-2019-124716

Published: 2019

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Blood (2019) 134 (Supplement_1): 1649.

https://doi.org/10.1182/blood-2019-127029

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Patrick Harrington, MRCP, FRCPath, Richard Dillon, MA, PhD MRCP, FRCPath, Philippe Rousselot, MD PhD, Deepti Radia, Yvonne Francis, Claire N Harrison, Professor, Shahram Kordasti, MD PhD, Hugues De Lavallade

Blood (2019) 134 (Supplement_1): 1635.

https://doi.org/10.1182/blood-2019-129135

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

Siddhesh Arun Kalantri, MD, Akanksha Chichra, DNB, Amit Kumar Agrawal, MDMDcine, Lingaraj Nayak, MDDM MDcal Oncology, Avinash Bonda, MD DM, Sachin Punatar, MBBS,MDDM MDcal Oncology, Anant Gokarn, MD, Bhausaheb Bagal, MD DM, Libin J Mathew, Sadhana Kannan, MSc, Navin Khattry, MD DM MDcal Oncology

Blood (2019) 134 (Supplement_1): 1983.

https://doi.org/10.1182/blood-2019-125029

Published: 2019

Journal Articles

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Mahmoud Hallal, BSc, MSc, Sophie Braga-Lagache, MSc, Jovana Jankovic, Rémy Bruggmann, PhD, Ramanjaneyulu Allam, PhD MSc, BSc, Mario P. Tschan, PhD, Cédric Simillion, PhD, Manfred Heller, PhD, Nicolas Bonadies, MD

Blood (2019) 134 (Supplement_1): 2079.

https://doi.org/10.1182/blood-2019-122337

Published: 2019

Journal Articles

Pricing of First and Second Generation Tyrosine Kinase Inhibitors (TKIs) Pre- and Post-Transition of Imatinib to Generic Status

Kelly Kenzik, PhD, Ravi Bhatia, MD, Smita Bhatia, MDMPH

Blood (2019) 134 (Supplement_1): 2140.

https://doi.org/10.1182/blood-2019-123490

Published: 2019

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Pratibha Bhatia, MSc, BSc, Sumeet Prakash Mirgh, MBBS,MDDM, Vishvdeep Khushoo, MBBS,MDDM, Faran Naim, MD DNB, Ambar Garg, MD DNB, Rayaz Ahmed, MDDM, Narendra Agrawal, MD DM, Dinesh Bhurani, MD DM, FRCPA

Blood (2019) 134 (Supplement_1): 3500.

https://doi.org/10.1182/blood-2019-131763

Published: 2019

Journal Articles

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Adi Shacham, MD, Lena Rosenman, Avi Leader, MD, Giora Sharf, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 4781.

https://doi.org/10.1182/blood-2019-129806

Published: 2019

Journal Articles

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Sean I. Tracy, MD PhD, Can Hekim, MSc,PhD, Michael Farrar, PhD

Blood (2019) 134 (Supplement_1): 1345.

https://doi.org/10.1182/blood-2019-124205

Published: 2019

Journal Articles

Real-World Treatment Patterns, Health-Care Costs and Predictors for TKI Changes in CML: Results from a Population Representative German Claims Data Analysis

Susanne Saussele, MD, Katharina Kohlbrenner, PhD, Thomas Kaworski, Tobias Vogelmann, MSc, Tino Schubert, MSc

Blood (2019) 134 (Supplement_1): 1645.

https://doi.org/10.1182/blood-2019-122649

Published: 2019

Journal Articles

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood (2019) 134 (Supplement_1): 1642.

https://doi.org/10.1182/blood-2019-130148

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

NARROW

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Pre-Transplant Use of Tyrosine Kinase Inhibitors Increases Risk of Transplant Associated Thrombotic Microangiopathy - a Single Centre Analysis of Incidence, Risk Factors and Outcomes

Characterization of Bypassing Kinases Inferred By Phosphoproteomics in a Midostaurin Resistant Myeloid Cell Line Model

Pricing of First and Second Generation Tyrosine Kinase Inhibitors (TKIs) Pre- and Post-Transition of Imatinib to Generic Status

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Effect of Depression on Health Related Quality of Life and Adherence and Its Correlation with Response Rates in Patients of Chronic Myeloid Leukemia on First Line Imatinib and Nilotinib - a Prospective, Institutional Analysis of Real World Data from India

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Characterization of BCR-ABL Specific CD4+ T Cells and Their Role in Controlling Ph+ Acute Lymphoblastic Leukemia

Real-World Treatment Patterns, Health-Care Costs and Predictors for TKI Changes in CML: Results from a Population Representative German Claims Data Analysis

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only